AdvanCell Pty Ltd, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, has appointed Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors.

Lee will head AdvanCell’s U.S. expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new U.S. headquarters near Boston/Cambridge, MA.

Lee succeeds founder and long-time CEO Andrew Adamovich, who will continue as Managing Director, Australia, and remain on the Board of Directors.

“Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, Chair of AdvanCell. “Her leadership and experience positions AdvanCell to drive its next phase of growth, with the United States now a major strategic focus as the company advances 212Pb-ADVC001 and its emerging pipeline of targeted alpha therapies in the world’s largest pharmaceutical market.”

Experience

Lee joins AdvanCell from Blueprint Medicines Corporation, recently acquired by Sanofi for approximately $9.5 billion. At Blueprint, she served as Chief Commercial Officer and was instrumental in driving the company’s strategy and building commercial infrastructure in oncology and mast cell disorders.

She also served on the Board of Directors of radiopharmaceutical company Fusion Pharmaceuticals Inc. and held senior roles in the U.S. at alpha therapy pioneer Algeta ASA, where she contributed to building the organization that successfully launched the first and only approved alpha therapy Xofigo (radium-223 dichloride) in the U.S. in collaboration with Bayer AG.

Lee earned a B.S. in Biochemistry from the University of Alberta, and a PhD in Cell Biology from the Massachusetts Institute of Technology.

“AdvanCell is pioneering a new class of targeted alpha therapies powered by 212Pb (Lead-212) with tremendous potential to transform cancer treatment and position the company as the leading targeted alpha radiotherapy company,” said Lee. “I am excited to accelerate the expansion of our U.S. leadership and operational capabilities, building on AdvanCell’s strong foundation in Australia and advancing our mission to transform care for cancer patients globally.”